Search company, investor...


Founded Year



Acquired | Acquired

Total Raised


About BioSeek

BioSeek is a drug discovery services company providing phenotypic screening technology that improves the success rate of pharmaceutical research and development by integrating primary cell profiling into the drug discovery process. The company's BioMAP Systems incorporate predictive primary human cell-based disease models that generate informative activity profiles of each potential drug, assisting in the selection and development of new drug candidates.In November 2012, BioSeek was acquired by DiscoveRx. The valuation of BioSeek was undisclosed. Other terms of the deal were not released.

Headquarters Location

310 Utah Avenue Suite 100

South San Francisco, California, 94080,

United States


Missing: BioSeek's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: BioSeek's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

BioSeek Patents

BioSeek has filed 1 patent.

patents chart

Application Date

Grant Date


Related Topics




Autoimmune diseases, Allergology, Pharmaceutical industry, Cell biology, Proteins


Application Date


Grant Date



Related Topics

Autoimmune diseases, Allergology, Pharmaceutical industry, Cell biology, Proteins



Latest BioSeek News

BioSeek secures $46.7m contract from US EPA

Sep 13, 2017

BioSeek secures $46.7m contract from US EPA Published 05 October 2012 Biotechnology company BioSeek has secured a $46.7m contract from the US Environmental Protection Agency (EPA) evaluate the human health effects of environmental chemicals, pesticides, failed pharmaceuticals, and nanomaterials, among other substances. The company will analyze up to 60,000 substance samples to evaluate the potential toxicity effects on the human body by using its cost-effective proprietary technology. Commenting on the contract BioSeek general manager Dr. Ellen Berg remarked that the combined efforts of the company and the agency are tuned towards ascertaining the effects of various environmental compounds on the human body. EPA awarded the contract under the agency's ToxCast program that seeks to verify the toxicity signatures of substances. "Our partnership with EPA under the ToxCast program has been a highly productive relationship with well over 1,000 samples, including chemicals, failed pharmaceutical compounds and nanomaterials analyzed to date," said Dr. Berg Share:

BioSeek Frequently Asked Questions (FAQ)

  • When was BioSeek founded?

    BioSeek was founded in 2000.

  • Where is BioSeek's headquarters?

    BioSeek's headquarters is located at 310 Utah Avenue, South San Francisco.

  • What is BioSeek's latest funding round?

    BioSeek's latest funding round is Acquired.

  • How much did BioSeek raise?

    BioSeek raised a total of $9.4M.

  • Who are the investors of BioSeek?

    Investors of BioSeek include DiscoverX, SImile Investors, Bay City Capital, Vanguard Ventures, Fremont Ventures and 3 more.

  • Who are BioSeek's competitors?

    Competitors of BioSeek include Carmot Therapeutics, DiscoveryBioMed, InterveXion Therapeutics, Melior Discovery, Echelon Biosciences, Ensol Biosciences, Actimis Pharmaceuticals, KineMed, Domainex, Transposagen Biopharmaceuticals and 15 more.

Compare BioSeek to Competitors

Echelon Biosciences Logo
Echelon Biosciences

Echelon Biosciences is a company that received a SBIR Phase I grant for a project entitled: Near Infrared Substrates for Imaging Autotaxin Activity In Vivo. Their project aims to synthesize ATXRed, an in vivo imaging agent that is specifically activated by the enzymatic activity of autotaxin. Autotaxin is an extracellular enzyme that generates the phospholipid growth factor lysophophatidic acid (LPA). LPA is involved in a variety of biological functions, such as angiogenesis, wound healing, brain development, immunological competence and the regulation of blood pressure. Both LPA and autotaxin have also been implicated in numerous diseases, especially metastatic cancer. Autotaxin was identified as one of the 40 most induced genes in aggressive breast cancer. The broader impacts of this research are the discovery and commercialization of tools that easily highlight specific biological pathways in living organisms. ATXRed will be welcomed by basic researchers in many fields associated with autotaxin and LPA. However, the utility extends beyond the basic research sphere. ATXRed smart probes could also aid pharmaceutical researchers searching for pharmacological inhibitors of autotaxin and LPA receptor agonists and antagonists. ATXRed would be a powerful tool in many rodent models of human cancer. In vivo autotaxin imaging probes could also aid in the clinic by helping to identify and monitor disease progression and treatment. Ultimately, ATXRed could help guide surgical resection of tumorstumors previously identified by the smart probe to have elevated autotaxin activity. In total, ATXRed probes have the potential to impact basic research, drug discovery and the clinic as a prime example of molecular medicine applied from bench to bedside.

Active Pass Pharmaceuticals

Active Pass is a Canadian biotechnology company that is engaging in genomic-based drug discovery and is developing drugs that inhibit ABC transporters. ABC or (ATP binding cassette) is a term that describes the interconnected group of molecular engines or pumps that function as a transportation system which moves compounds across the biological membranes. These ABCs are very closely associated with human diseases like Alzheimer's disease, diabetes, asthma, and hypertension. The Active Pass management team is an accomplished group with experience in many aspects of drug discovery and development. Besides employing full time pharmaceutical development professionals, Active Pass has made wise use of a group of several key partnerships with different pharmaceutical groups. The company cultivates these partnerships in order to access new capabilities or expertise to advance the company's own technologies. More specifically, these partnerships include the Vaccines and Infectious Diseases Organization as well as the National Institute of Health). The company hopes to add new personnel to cover emerging areas of emphasis like clinical and regulatory affairs, business development and finance as they grow.


VivoPath is a preclinical screening company, offering the company's clients discovery and development services for in vivo testing. VivoPath aims to provide integrated in vivo studies led by established experts in drug development. Efficacy is established for animal models in the areas of metabolic disease, inflammation, neurodegenerative disease, and infectious diseases. Formulation screening is carried out to select the most appropriate delivery system for administration. Pharmacokinetic evaluation is carried out to assess exposure and bioavailability. Tolerability is assessed with evaluations of clinical signs, clinical chemistry and hematology. The resulting program aims to deliver the client an in vivo therapeutic index (TI) report on which to assess candidates for subsequent development. VivoPath can also help clients at any individual step in this preclinical screening process. VivoPath's commitment is to provide scientific expertise in in vivo drug discovery in order to increase productivity from research into drug development.

Welichem Biotech

Welichem Biotech Inc. ("Welichem", TSX-V: WBI) is engaged in the discovery and development of small molecule therapeutics. Using its Symbiochem technology platform, the Company has developed a robust pipeline of patent-protected compounds that target autoimmune/inflammatory diseases and cancers. Welichem's lead drug candidate, WBI-1001, targets autoimmune/inflammatory skin disorders, such as psoriasis and eczema. A phase I clinical trial of WBI-1001, done in Montreal, in patients with psoriasis has shown a very good safety profile and promising efficacy. As well, the application of WBI-1001 cream against atopic dermatitis (a type of eczema) in a phase IIa clinical trial also has been completed in Canada, with the final report pending in the third quarter of 2008. Welichem plans to all the necessary Phase II Clinical Trials against psoriasis and eczema in the near future. In the company's pipeline, WBI-1001 related compounds are being evaluated also for their therapeutic potential against other autoimmune diseases such as, inflammatory bowel disease and rheumatoid arthritis. Welichem's other lead drug candidate, WBI-2100, selectively targets certain types of hard-to-treat cancerous tumours. This is achieved in part through inhibition of angiogenesis and metastasis. Animal tests have shown that WBI-2100 is effective as a monotherapy and also in increasing the effectiveness of several commonly used chemotherapeutic products. The uniqueness of this small molecule cancer chemotherapeutic is that in pre-clinical studies it increases the number of neutrophils in the peripheral blood. The boosting of neutrophils in animal studies in the presence of the cancer therapeutic, cyclophosphamide, supports its potential therapeutic application for chemotherapy induced neutropenia. With its proven Symbiochem; technology platform, Welichem will advance its pipeline of drug candidates at a rate and time commensurate with resources and target need, and is in a strong position to contribute effectively to productive drug discovery and development partnerships.

Medicor Biosciences

Medicor Biosciences, founded in 2006 is a development-stage company focused on drug discovery for combating cancer. The founding scientists are leaders in a class of anti-hormone drugs that are designed to block the relaxin hormone cellular signaling pathways in a number of different cancer types. Using the company's Relaxofen technology platform, therapeutic candidates are generated by engineering the natural relaxin peptide to display antagonistic properties. Through pre-clinical development and clinical trials, Medicor Biosciences plans to develop and potentially license the technology so that the therapeutics can be available for cancer patients as an anti-hormone therapy to impair the growth and spread of the disease.


Kalypsys is a drug discovery company using a cellular ultra high-throughput system to carry out massive drug screening in cellular models of human disease and toxicology.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.